Mylan N.V., a leading global pharmaceutical company whose ordinary shares (“Mylan Shares”) are traded on the NASDAQ Global Select Market and the Tel Aviv Stock Exchange under the symbol “MYL”, has today announced a public offer to the shareholders of Meda to transfer all of their shares in Meda to Mylan for a consideration consisting of a combination of cash and Mylan Shares (the “Offer”). Mylan is offering each Meda shareholder.Read more
Armolipid PLUS was launched in January 2016Read more
The EndWarts PEN was launched in May 2015.Read more
In April 2015, Meda Health Sales launched CB12 Toothpaste.Read more
Meda Health Sales, in June 2014, launched the new 500ml bottle of CB12 oral rinse. This retails at €19.99 and is a further development of the CB12...Read more
In March 2014 Meda Health Sales launched a new product in the CB12 range, CB12 Boost Chewing Gum.
- Supplement to CB12 mouth wash
- Sugar free chewing gum
Owen McKeon, Country Manager, Ireland & UKRead more
Meda Health Sales extended their range of CB12 products by introducing CB12 250ml Oral Rinse Mild and CB12 50ml Oral Rinse (Travel Size).Read more
Meda launched Endwarts; a new OTC treatment for warts and verrucas.
The active ingredient is Formic Acid and the product is available in all...